DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Boehringer Ingelheim

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Glucagon-like peptide 1 agonist; Drug: Dipeptidyl-peptidase 4 inhibitor; Drug: Sodium Glucose Transporter 2 inhibitor; Drug: Empagliflozin

Study type: Observational

Funder types: Industry

Identifiers

NCT03807440

1245-0187

Details and patient eligibility

About

This is a non-interventional study using existing data including medical chart review.

Enrollment: 4,083 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Written informed consent prior to participation
2. Female and male patients age ≥ 18 years
3. Patients with T2D diagnosis
4. Patients who have been newly initiated (first ever use) with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) between September 2018 and December 2018 (study index date 1)
5. Patients have been naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) at study index date 1

Exclusion criteria

1. Patients age < 18 years
2. Patients with diagnosis of other types of diabetes than T2D
3. Patients who do not provide written consent to the terms of the study

Trial design

4,083 participants in 1 patient group

Subjects with Diabetes Mellitus, Type 2

Treatment:

Drug: Sodium Glucose Transporter 2 inhibitor

Drug: Empagliflozin

Drug: Dipeptidyl-peptidase 4 inhibitor

Drug: Glucagon-like peptide 1 agonist